Sernivo Generic Name & Formulations
Betamethasone (as dipropionate) 0.05%; spray.
Mild to moderate plaque psoriasis.
Sernivo Dosage and Administration
≥18yrs: apply to affected areas twice daily for up to max 4 weeks; discontinue when control is achieved. Do not occlude.
<18yrs: not recommended.
Sernivo Boxed Warnings
Not for oral, ophthalmic, or intravaginal use. Avoid use on face, scalp, axilla, groin, or other intertriginous areas. Do not use on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Potential risk of posterior subcapsular cataracts and glaucoma. Avoid abrupt cessation in chronic use. Reevaluate periodically. Pregnancy. Nursing mothers: avoid infant exposure.
Sernivo Adverse Reactions
Pruritus, burning, stinging, pain, atrophy; allergic contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children), visual disturbances; rare: Cushing's syndrome, hyperglycemia, glucosuria.
Sernivo Clinical Trials
Sernivo Patient Counseling